Description
Dispensaries are an important retail channel for cannabis in the US, as customers are generally there to solely purchase cannabis products. They are also important because they are the only places that can legally sell cannabis under individual state law. However, some states have a requirement that only allows the sale of heavily tested cannabis products, requirements that other hemp products would not meet. This report looks at which states allow the sale of intoxicating hemp-derived cannabinoids (IHDCs) in dispensaries.
Reasons to buy
Intoxication hemp-derived cannabinoids (IHDCs) have been major disruptors in the CBD and legal cannabis sectors in the US for some time now, with a number of states deciding to regulate their sale rather than banning them. If you are interested in IHDCs and their status in the US, then this report offers invaluable information about which states allow their sale in cannabis dispensaries. It also looks at which states have dispensaries offering them, regardless of whether they are permitted.
Table of contents
- Executive summary
- Introduction
- Availability of IHDCs in dispensaries
- State-by-state regulation
- Alabama
- Alaska
- Arizona
- Arkansas
- California
- Colorado
- Connecticut
- Delaware
- Florida
- Hawaii
- Illinois
- Iowa
- Louisiana
- Maine
- Maryland
- Massachusetts
- Michigan
- Minnesota
- Mississippi
- Missouri
- Montana
- Nevada
- New Hampshire
- New Jersey
- New Mexico
- New York
- North Dakota
- Ohio
- Oklahoma
- Oregon
- Pennsylvania
- Rhode Island
- South Dakota
- Utah
- Vermont
- Virginia
- Washington
- West Virginia
Methodology
The research is completely original and conducted by CBD-Intel’s multilingual legal analysis team using several sources, including online and offline resources and data, specialist legal software, interviews with key stakeholders and government officials, and via the collaboration with local lawyers and on-the-ground professionals.